N/A N=40 Early Postoperative Compex Rehab NMES Use for Total Knee Arthroplasty Patients
Knee Osteoarthritis
Primary: Change in Quadriceps Force — 49.0; 28.4 Newtons (N)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model
Malaria
Primary: Cohort 1: Number of TEAEs — 2; 1; 4; 1 Participants
Phase 2 N=307 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID)…
Phase 3 N=28 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
Cannabis Use Disorder · Attention-deficit/Hyperactivity Disorder
Primary: Marijuana Abstinence — 0; 2 Participants
N/A N=142 Sexual Function and Wellbeing in Females With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and 1 Year After Surgery. — 0.6; 0.6; 0.6; 0.5 nmol/l — p=0.004
N/A N=69 The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Tear Film Breakup Time — 4.65; 4.42 seconds — p=0.550
Phase 1 N=9 Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
Multiple Myeloma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1 — 1 Participants
N/A N=349 Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis Pain
Knee Osteoarthritis
Primary: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From Baseline — -5.87; -5.97 units on a scale
N/A N=66 A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Verruca Viral
Primary: Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts — 25; 22; 2; 6 Participants
Phase 2 N=54 Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer
Relapsed Bladder Cancer
Primary: Non-progression Rate at 2 Months — 48.9 percentage of participants
Phase 2 N=411 Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
Drug-resistant Epilepsy · Focal-Onset Seizures
Primary: Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period — -0.27585; -0.46424; -0.48804; -0.48960 loge…
N/A N=3,443 IMPACT (Improving Plasma Collection) Clinical Trial
Apheresis Related Hypotension
Primary: Rate of Significant Hypotensive Adverse Events — .035; .051 % of significant hypotensive AEs
Phase 3 N=493 Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Therapeutic Cure (Clinical + Microbiological Cure) — 63; 49; 20 Participants
N/A N=152 Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019
COVID-19
Primary: Hierarchical Composite Endpoint — 81; 73 score on a scale (range 1 to 152)
Phase 2 N=74 Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Mesothelioma · BAP1 Loss of Function
Primary: Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax — 933 Ng/mL